On November 4, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the third quarter ended September 30, 2026. A copy of such press release is being furnished as Exhibit 99.1 to this report.
|
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for oncology and complement-related conditions. Its pipeline includes NXP900, an oral small molecule inhibitor of SRC and YES1 kinases, currently in Phase 1b trials for advanced solid tumors such as breast, colon, prostate, and lung cancers. NXP900 is being evaluated as a single agent and in combination with EGFR and ALK inhibitors. The company also develops NXP100, a complement Factor B inhibitor for diseases caused by dysregulated complement activity, and NXP200, a paradox breaker BRAF inhibitor for advanced cancers. NXP800, a GCN2 kinase activator, is under evaluation for platinum-resistant ovarian cancer and cholangiocarcinoma. Nuvectis Pharma was formerly known as Centry Pharma, Inc. and was founded in 2020. The company holds worldwide commercial rights to NXP900, licensed from the University of Edinburgh. Summarised from the company's own disclosures, fiscal year ended Feb 2026 |
Industry Biotechnology | Homepage nuvectis.com |
| Sector Healthcare | IR page nuvectis.com/investors | |
|
Tags
oncology, precision medicine, kinase inhibitors, complement inhibitors, solid tumors, src kinase, yes1 kinase, braf inhibitor, clinical-stage, small molecule, NXP900, NXP100, NXP200, NXP800, Centry Pharma Inc.
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 726.294M |
| Market cap (USD) | $ 726.294M |
| P/E | -11.17 |
| PEG | — |
| P/BV | 5.73 |
| P/S | — |
| P/OCF | -18.02 |
| P/FCF | -45.37 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -188.0% |
| ROI | -143.6% |
| ROIC | -112.3% |
| Profit margin | — |
| Growth | |
|---|---|
| Revenue growing | — |
| Profits growing | No |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | — |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 5 |
| Quality score | -83.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Balance sheet detail | |||||
| Cash and deposits (USD) | 5.74M | 20M | 19.1M | 18.5M | 31.6M |
| Cash flow detail | |||||
| Operating cash flow (USD) | -9.5M | -13.6M | -16M | -12.2M | -16M |
| Change in payables (cash effect) (USD) | 1.59M | 4.14M | -139,000 | -273,000 | 3.78M |
| Share-based compensation (USD) | 1.89M | 1.71M | 4.71M | 4.86M | 6.03M |
| Income detail | |||||
| Research and development expense (USD) | 9.55M | 13.2M | 15.4M | 12.9M | 18.2M |
| Reported | Mar 8, 2023 | Mar 8, 2023 | Mar 5, 2024 | Feb 25, 2025 | Feb 11, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
Skip To Main Content
This website is AudioEye enabled and is being optimized for accessibility. To open the AudioEye Toolbar, press "shift + =". Some assistive technologies may require the use of a passthrough function before this keystroke. For more information, activate the button labeled "Explore your accessibility options".
Customize Consent Preferences
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... Show more
NecessaryAlways Active
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Uncategorized
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Reject All Save My Preferences Accept All

Nuvectis Pharma
Precision Medicine for the Treatment of Complement Related Diseases and Cancer
Explore our pipelineInvestor Relations
Innovative precision medicine for the treatment of complement-related conditions and oncology
Nuvectis Pharma (Nasdaq: NVCT) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. Our lead candidate is ciprocopan, a Factor B inhibitor for once daily oral administrations, with best-in-class potential, approved in China in July 2026 for treatment of PNH in patients previously untreated with complement inhibitors. Our oncology pipeline includes NXP200 (paradox breaking, BRAF kinase inhibitor) and NXP900 (YES1/SRC kinase inhibitor) for the treatment of advanced cancers.
PipelineOur complement and oncology programs, from mechanism to clinic.Learn more
LeadershipMeet the management team and board of directors.Learn more
Investor RelationsStock information, filings, events and presentations.Learn more
Pipeline
Our programs
ComplementNXP100Complement Factor B InhibitorNXP100 is a small molecule for oral, once daily administration that inhibits Factor B, a critical protease within the alternative pathway of the complement cascade.View program
OncologyNXP200Paradox Breaker BRAF InhibitorNXP200 is an oral small-molecule, paradox breaker BRAF inhibitor.View program
OncologyNXP900SRC/YES1 Kinase InhibitorNXP900 is an oral small-molecule inhibitor targeting the SRC Family of Kinases (SFKs), with low nanomolar potency for SRC and YES1.View program
News
Latest Press Releases
November 4, 2026Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business HighlightsRead moreNovember 2, 2026Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026Read moreOctober 26, 2026Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive GliomasRead moreOctober 9, 2026Nuvectis Pharma to Participate in the Maxim Growth Summit 2026Read moreSeptember 24, 2026Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade GliomaRead moreSeptember 3, 2026Nuvectis Pharma To Participate in Upcoming Investor ConferencesRead moreAugust 4, 2026Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business HighlightsRead moreJuly 23, 2026Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement InhibitorsRead more

Email Alerts
Stay informed
Get Nuvectis press releases and SEC filings delivered to your inbox.
Opens in new window
PDF Download
Word Download
Excel Download
PowerPoint Download
Document Download
Explore your accessibility options
Skip To Main Content
This website is AudioEye enabled and is being optimized for accessibility. To open the AudioEye Toolbar, press "shift + =". Some assistive technologies may require the use of a passthrough function before this keystroke. For more information, activate the button labeled "Explore your accessibility options".
Customize Consent Preferences
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... Show more
NecessaryAlways Active
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Uncategorized
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Reject All Save My Preferences Accept All

Nuvectis Pharma
Precision Medicine for the Treatment of Complement Related Diseases and Cancer
Explore our pipelineInvestor Relations
Innovative precision medicine for the treatment of complement-related conditions and oncology
Nuvectis Pharma (Nasdaq: NVCT) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. Our lead candidate is ciprocopan, a Factor B inhibitor for once daily oral administrations, with best-in-class potential, approved in China in July 2026 for treatment of PNH in patients previously untreated with complement inhibitors. Our oncology pipeline includes NXP200 (paradox breaking, BRAF kinase inhibitor) and NXP900 (YES1/SRC kinase inhibitor) for the treatment of advanced cancers.
PipelineOur complement and oncology programs, from mechanism to clinic.Learn more
LeadershipMeet the management team and board of directors.Learn more
Investor RelationsStock information, filings, events and presentations.Learn more
Pipeline
Our programs
ComplementNXP100Complement Factor B InhibitorNXP100 is a small molecule for oral, once daily administration that inhibits Factor B, a critical protease within the alternative pathway of the complement cascade.View program
OncologyNXP200Paradox Breaker BRAF InhibitorNXP200 is an oral small-molecule, paradox breaker BRAF inhibitor.View program
OncologyNXP900SRC/YES1 Kinase InhibitorNXP900 is an oral small-molecule inhibitor targeting the SRC Family of Kinases (SFKs), with low nanomolar potency for SRC and YES1.View program
News
Latest Press Releases
November 4, 2026Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business HighlightsRead moreNovember 2, 2026Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026Read moreOctober 26, 2026Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive GliomasRead moreOctober 9, 2026Nuvectis Pharma to Participate in the Maxim Growth Summit 2026Read moreSeptember 24, 2026Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade GliomaRead moreSeptember 3, 2026Nuvectis Pharma To Participate in Upcoming Investor ConferencesRead moreAugust 4, 2026Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business HighlightsRead moreJuly 23, 2026Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement InhibitorsRead more

Email Alerts
Stay informed
Get Nuvectis press releases and SEC filings delivered to your inbox.
Opens in new window
PDF Download
Word Download
Excel Download
PowerPoint Download
Document Download
Explore your accessibility options
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Nuvectis Pharma, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| FSEG | 0.07% | 207 | $ 3,806.73 | Jun 30, 2026 |